The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. - Wikidata - awgldk - TriplyDB

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.

http://www.wikidata.org/entity/Q43215888

about

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma Emerging immunologic biomarkers: setting the (TNM-immune) stage.New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.Targeting the PD-1 pathway: a promising future for the treatment of melanoma.Considerations for combined immune checkpoint modulation and radiation treatment.Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.A novel minigene scaffold for therapeutic cancer vaccines Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model.The predictive value of centre tumour CD8⁺ T cells in patients with hepatocellular carcinoma: comparison with Immunoscore Doubling the blockade for melanoma immunotherapy The Basis of Oncoimmunology Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer The prognostic yield of biomarkers harvested in chemotherapy-naive stage II colon cancer: can we separate the wheat from the chaff?Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid Inhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond.Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays.Monitoring the immune competence of cancer patients to predict outcome.Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.New clinical advances in immunotherapy for the treatment of solid tumours.Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.Monitoring immune-checkpoint blockade: response evaluation and biomarker development.Melanoma exosomes deliver a complex biological payload that upregulates PTPN11 to suppress T lymphocyte function.Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1(+) and CD8(+) tumor-infiltrating T cells and outcome.Prognostic value of immunoscore to identify mortality outcomes in adults with HBV-related primary hepatocellular carcinoma.Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.Cancer immunotherapy: A need for peripheral immunodynamic monitoring.Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma.Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial.

P2860

Q26765115-F9E79E5B-2342-4F55-8B97-439503D4DFD0 Q26777403-25E87C5D-C6ED-4BB4-BB17-B757E2C432B2 Q26800814-4B4B70B9-F9CC-4D14-8AB3-D02463BFB322 Q33677916-44DEB511-4AEB-4DCB-BFFA-F88514EB4C6E Q33704088-C23D8468-712C-4BFB-81E7-B58B55C3B94F Q33839204-2DE3FE25-CFE6-4BAC-91A0-4620A4D3C15C Q33946513-0AA49AAF-D27F-469F-AE5B-68058556C2E7 Q34174871-2F0FD82C-10C1-47B8-9F06-B13008501372 Q34278609-386EA79D-9245-4ACA-93C8-AD425D37FE26 Q34418540-A9805A67-78D9-4866-877D-80FF3AD9867F Q34515007-9896A3A5-5257-49A7-8328-78BFD71750FB Q34563201-B52D6C9F-6EA4-40AF-860F-E56071E7DC34 Q35078852-E70DC86B-F3F2-4849-9422-BEAC87339678 Q36062936-03001961-B9A1-4E7A-BFDF-F6FA9023A1B1 Q36546411-DBE3501D-01D9-4E3B-9D94-957E138A7336 Q36597356-4DAD0CCA-7DA5-4CBD-A35C-DB11294398A1 Q36678851-88317167-578B-4625-B8ED-B23893C4D346 Q36824656-D6952032-8F13-420B-963A-48EFB3635FB0 Q37233874-FB94862A-2697-4FB8-B5C5-C151F66152BA Q37256316-CA1AB580-8020-4CF6-829E-B172945609F5 Q37620006-E9B0A844-ED88-428F-9B81-2A5CD3B2805D Q37697529-78E568CD-74DC-4834-99F7-573B8D66F3F7 Q37739214-7186B892-3C01-444F-BE1D-5AF8BD24E0E4 Q38120535-71BFB981-452E-4104-B8CC-2400A0042CD0 Q38160232-5CB2F358-9BDB-4165-AA9D-E5C4FBB00304 Q38184391-3019F9B0-1848-42AB-9A5B-72A970668722 Q38312053-E5EBF652-6B5A-4D69-BC5D-A4714926ECE6 Q38397279-B9CEA840-E94A-4B66-8A8C-F22CE28FD82D Q38441450-40322765-DDCA-4E71-AFF2-151AB19FF2D4 Q38666241-0FDDA116-B2C6-4746-9073-4CA5918D2FF7 Q38727129-D1FEE726-0162-4802-B41D-3A15FBBBBC45 Q38749966-AB9C97AE-C422-4E86-99B2-FE4C037C9A75 Q38754407-3E8DA545-9FF8-4AED-A541-B684032AF99E Q39452745-00D68C4B-10B5-456C-85E0-B491111D580B Q40227043-370B5C12-86A4-44D1-ABB7-DE9883EDC1F7 Q41613259-AA37D1B0-ACE4-49B9-81B3-27D94182DC91 Q47561904-02EC6D17-0F66-4CBD-87E4-793D7A63C763 Q47936526-BE31D47B-2EF4-444E-986D-E154F9B3311B Q49181142-4CAFA8EC-97A0-414E-B675-FF080454ECB4 Q51529309-94EBC28F-C417-4AAF-870B-DF80C8888E82

P2860

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.

http://www.wikidata.org/entity/Q43215888

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

The additional facet of immuno ...... ive tool for cancer treatment.

@en

The additional facet of immuno ...... ive tool for cancer treatment.

@nl

type

label

The additional facet of immuno ...... ive tool for cancer treatment.

@en

The additional facet of immuno ...... ive tool for cancer treatment.

@nl

prefLabel

The additional facet of immuno ...... ive tool for cancer treatment.

@en

The additional facet of immuno ...... ive tool for cancer treatment.

@nl

P1433

Q43215888-FAC28A92-AF5E-4186-977C-5E0B290AE3C9

P1476

Q43215888-0C43D33A-F172-499A-89D3-E1ADA11B4BF3

P2093

Q43215888-2EF3EEB2-0B8F-431F-ABC0-705E8CEEC6DC

Q43215888-77F2AC31-D3CB-490D-B522-3E52DEB00025

Q43215888-97677B26-815A-4A75-8C84-CB81C3B47E0A

Q43215888-B0A93299-F14C-44A6-9225-6282405C2DAF

Q43215888-C80E4924-4125-4F31-BB6D-9B8CDA677377

P2860

Q43215888-11FE1EBA-7F40-4FF5-9372-9CBCA16388F9

Q43215888-21748F1C-EB62-4FBC-B3EB-534F2D408A91

Q43215888-2D231C9A-D41B-4FB9-BC09-EA64E3AADC71

Q43215888-40A0A1EE-E192-4C17-B41E-4261988E84BD

Q43215888-429FC316-C14A-4A13-A51C-B472BAA79864

Q43215888-481C8C06-8306-4C19-B03D-1AB0079A7083

Q43215888-4BCD34E5-2ED6-4DC4-8A18-2B8C7B395C1D

Q43215888-54BC4FF8-CA1A-429D-AB1A-865E40D750A5

Q43215888-60DA0C76-2018-41DE-844C-962CD9AC7343

Q43215888-70CA7084-9ADA-47B5-B462-C89C42C0B0BD

P2888

Q43215888-B7E660E4-7460-4785-A4C2-C98620BAE7F4

P304

Q43215888-D182C661-0720-4784-A0FB-0833340E4982

P31

Q43215888-64959974-55E7-49E5-BD7F-1111FEBFD417

Q43215888-d527ef74-d8ea-4ce8-82ff-746e40c04313

P356

Q43215888-BCCB3204-8463-490C-AB9B-DD91FC637A07

P478

Q43215888-987E0D18-EBA4-466B-BA4A-9A06323A2D84

P50

Q43215888-1145A027-FC35-4455-A54E-F8E5308D17C6

Q43215888-54302891-CA30-4269-A7A8-90F850FC8DAC

Q43215888-752D8086-3DA2-441B-BB9D-BFBAF607F6AE

Q43215888-ACB44ED0-A252-4BCB-AB9E-C5C52C0B0890

Q43215888-F43AE819-FE27-4AAC-886A-B81B6319B3C0

P577

Q43215888-7E46B44A-C65F-495C-8853-991E84918091

P5875

Q43215888-3975B643-231C-4FF7-9AFB-B7C4716AB0BF

P6179

Q43215888-DF37CAAD-2D15-4919-B4BA-0726D19EC121

P698

Q43215888-C5DA740B-8B5A-4BF9-B372-9E938C924F7A

P932

Q43215888-55F400A3-0F45-4C23-A19B-EB3F750B5A31

P356

1479-5876-11-54

P1433

Journal of Translational Medicine

P1476

The additional facet of immuno ...... ive tool for cancer treatment.

@en

P2093

Alessandro Lugli

http://www.w3.org/2001/XMLSchema#string

Bernard A Fox

http://www.w3.org/2001/XMLSchema#string

Carlo B Bifulco

http://www.w3.org/2001/XMLSchema#string

Francesco M Marincola

http://www.w3.org/2001/XMLSchema#string

Walter J Urba

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Science gone translational: the OX40 agonist story

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

The immune contexture in human tumours: impact on clinical outcome

Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer

Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.

Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

P2888

1479-5876-11-54

P304

54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-11-54

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Mariaelena Capone

Gennaro Ciliberto

Paolo Antonio Ascierto

P577

2013-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235773555

http://www.w3.org/2001/XMLSchema#string

P6179

1049399339

http://www.w3.org/2001/XMLSchema#string

P698

23452415

http://www.w3.org/2001/XMLSchema#string

P932

3608225

http://www.w3.org/2001/XMLSchema#string